TACE Combined with Apatinib is Safe and Effective for the treatment of BCLC Stage C Hepatocellular Carcinoma
Transcatheter arterial chemoembolization (TACE) combined with apatinib (TACE-apatinib) prolonged time to progression (TTP) and overall survival (OS) compared to TACE-alone for Barcelona Clinic Liver Cancer (BCLC) stage C HCC, according to a study published in BMC Cancer.
This retrospective study reviewed 80 consecutive patients with BCLC stage C HCC whose initial treatment consisted of TACE-apatinib or TACE-alone. Clinical and laboratory outcomes, tumor response, TTP, OS, adverse events, and imaging findings at 1 and 3 months after TACE were compared between the groups.
In the TACE-apatinib group, overall response rate was 66.7% at 1 month and 39.6% at 3 months after treatment (P = 0.020) compared with 45.8% at 1 month and 17.6%, at 3 months after treatment (P = 0.021). The median TTP was 6.3 months in the TACE-apatinib group and 3.5 months in the TACE-alone group (P = 0.002). Overall survival was 13.0 months in the TACE-apatinib group and 9.9 months in the TACE-alone group (P = 0.041).
The TACE-apatinib group experienced more side effects, such as hypertension, hand-foot syndrome, oral ulcers, proteinuria, and diarrhea, than in TACE-alone group (P < 0.05).
The authors concluded that, “compared to TACE-alone treatment, TACE-apatinib increased the TTP, OS, and tumor-response rate at 1 and 3 months after treatment of BCLC stage C HCC without any significant increase in severe adverse events.”
Chen S, Yu W, Zhang K, Liu W. Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma. BMC Cancer. 2018;18(1):1131. doi: 10.1186/s12885-018-5081-3.